December 16, 2020
MAINZ, GERMANY, and SHANGHAI, CHINA, December 16, 2020 (GLOBE NEWSWIRE) — BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma” or “Group”; Stock Code: 600196.SH,
02196.HK) today announced an agreement to supply
Mainland China with an initial 100 million doses of their BNT162 mRNA-based vaccine candidate against COVID-19 in 2021, subject to regulatory approval. Initial supply will be delivered from BioNTech’s production facilities in Germany.
https://investors.biontech.de/news-releases/news-release-details/biontech-and-fosun-pharma-supply-china-mrna-based-covid-19
https://www.fosunpharma.com/en/news/news-details-3820.html
仲有篇新聞入面
In response to Guo’s comments, Chuang Jen-hsiang, a spokesman for Taiwan’s Central Epidemic Command Center, said that the government had spoken directly to all vaccine providers including BioNTech. “There is no message from BioNTech to us saying that we should talk to Fosun instead,” he said.
Taiwan has already signed off on a supply deal with BioNTech, it’s just waiting for the company to respond, Chuang said.
信復星講 定信一開始announce